Business Context and Reporting Period
Company: American Shared Hospital Services
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2001
Business Overview: The Company provides Gamma Knife units to medical centers through fee-per-use contracts and revenue-sharing agreements. As of March 31, 2001, the Company operated ten Gamma Knife units across the United States. The Company also maintains two startup businesses, OR21 and MedLeader.
Key Financial Metrics
| Metric | Q1 2001 | Q1 2000 |
|---|---|---|
| Revenues (Medical Services) | $2,860,000 | $2,098,000 |
| Net Income | $417,000 | $391,000 |
| Earnings Per Share (Basic) | $0.12 | $0.10 |
| Earnings Per Share (Diluted) | $0.08 | $0.07 |
| Net Cash from Operating Activities | $1,200,000 | $393,000 |
| Cash and Cash Equivalents (End of Period) | $12,214,000 | $12,698,000 |
| Total Assets | $40,604,000 | N/A |
| Total Debt (Current + Long-term) | $25,121,000 | N/A |
| Working Capital | $9,776,000 | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Medical services revenue increased by $762,000 (36%) compared to Q1 2000. This was driven by the addition of two new Gamma Knife units (totaling 10 units vs. 8 in the prior year) and a 17% increase in utilization at existing units.
- Expense Increases: Total costs and expenses rose by $651,000. Notable increases included:
- Costs of Operations: Increased $305,000 due to maintenance contracts expiring on older units, higher depreciation from new units, and increased insurance/marketing costs.
- Selling and Administrative: Increased $261,000, primarily due to $120,000 in development costs for startups OR21 and MedLeader and increased travel expenses.
- Interest Expense: Increased $85,000 due to financing for the two new Gamma Knife units.
- Net Income: Increased by $26,000 (7%) to $417,000, despite higher operating and interest costs.
- Cash Flow: Net cash provided by operating activities improved significantly to $1.2 million from $393,000 in the prior year, largely due to a decrease in accounts receivable.
Guidance, Outlook, and Risks
- Dividends and Buybacks: The Company paid its first annual dividend of $0.10 per share ($361,000 total) and repurchased 113,000 shares of stock for $265,000 during the quarter.
- Tax Outlook: The Company recorded no income tax expense in Q1 2001 due to net operating loss carryforwards. Management expects to begin recording an income tax provision in the second quarter of 2001 if income levels remain consistent.
- Liquidity: The Company holds $12.2 million in cash and cash equivalents. Management believes cash flow from operations and existing resources are adequate to meet scheduled debt obligations of approximately $6.5 million due in the next 12 months.
- Investment Strategy: Excess cash is invested in overnight repurchase agreements and commercial paper.
- Risks/Contingencies: No legal proceedings or defaults on senior securities were reported. The Company notes that results for the three-month period are not necessarily indicative of annual results.
Investor Verification Checklist
- Revenue Sustainability: Verify the utilization rates of the two new Gamma Knife units added in the prior year to ensure the 36% revenue growth is sustainable.
- Startup Costs: Monitor the $120,000 quarterly development spend for OR21 and MedLeader to assess the timeline for profitability or further capital requirements.
- Tax Liability: Confirm the timing and magnitude of the expected income tax provision starting in Q2 2001, which will impact net income margins.
- Debt Servicing: Review the schedule of $6.5 million in debt payments due within 12 months against projected operating cash flows.
- Share Count: Note the reduction in outstanding shares due to the repurchase of 113,000 shares, which may impact future earnings per share calculations.